Warfarin and Breastfeeding
Lactating mothers can safely continue warfarin therapy while breastfeeding without monitoring the infant's coagulation status. 1
Evidence Supporting Safety
The American College of Chest Physicians (ACCP) guidelines explicitly state that warfarin use in women requiring postpartum anticoagulant therapy is safe based on compelling pharmacologic and clinical evidence 1:
- Warfarin is not detected in breast milk due to its polar, non-lipophilic properties and high protein binding 1
- No anticoagulant effect occurs in breastfed infants when nursing mothers consume warfarin, demonstrated in two convincing reports 1, 2
- Research confirms warfarin levels in breast milk are below detectable limits (<0.08 micromol/L or 25 ng/mL) 3
Infant Monitoring Considerations
The FDA label notes that while warfarin has not been detected in breast milk, it is prudent to perform coagulation tests and evaluate vitamin K status in infants before advising women taking warfarin to breastfeed 4. However, this represents a cautious medicolegal position rather than evidence-based necessity.
Practical approach:
- Routine infant coagulation monitoring is not required based on guideline evidence
- Consider baseline coagulation testing if there are clinical concerns about the infant
- Ensure standard vitamin K supplementation (25 micrograms daily) for all breastfed infants 5
- Monitor maternal PT/INR carefully to maintain therapeutic range 4
Important Caveats
Avoid other vitamin K antagonists: Less commonly used agents (phenindione, anisindione, phenprocoumon) ARE excreted in breast milk and could affect neonatal hemostasis—these should be avoided 1, 5
Maternal monitoring remains essential: Women who are breastfeeding and anticoagulated with warfarin should be very carefully monitored to ensure PT/INR values remain in therapeutic range 4
Postpartum dosing changes: Be aware that warfarin dose requirements may increase substantially postpartum (up to 100% higher than pre-pregnancy doses), particularly in breastfeeding women, requiring close INR monitoring and dose adjustments 6
Contrast with Direct Oral Anticoagulants (DOACs)
Unlike warfarin, DOACs (dabigatran, rivaroxaban, apixaban) are not recommended during breastfeeding due to insufficient safety data, breast milk excretion in animal studies, and manufacturer recommendations against use 1, 7. This makes warfarin the preferred oral anticoagulant for lactating women requiring anticoagulation.